Immunotherapy plus chemo vs chemo alone for high-risk colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your colon cancer is MSS (microsatellite stable) — it does not have many DNA errors.
- Your cancer is high-risk: either growing through the bowel wall (T4) or has spread to nearby lymph nodes (N+).
- The tumor is at least 12 centimeters from your anus and can't be felt during a rectal exam.
- You have not had any previous cancer treatment, and your overall health is good (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This Phase 2 trial studies giving chemotherapy plus immune therapy before surgery for certain colon cancers that do not have mismatch repair defects (MSS/pMMR). The goal is to shrink and control the tumor and improve outcomes compared with standard approaches.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Hear when a new Colonic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.